Systematic Review of the Efficacy of Acarbose Treatment in Impaired Glucose Tolerance

VernacularTitle:阿卡波糖治疗糖耐量损伤疗效的系统评价
Author: Liqing CHAI ; Airong YAN
Publication Type:Journal Article
Keywords: Acarbose; Impaired glucose tolerance; Meta-analysis; Efficacy
From: China Pharmacy 2015;(18):2509-2512
CountryChina
Language:Chinese
Abstract: OBJECTIVE:To evaluate the efficacy of acarbose treatment in impaired glucose tolerance (IGT)and provide evi-dence-based reference for the clinical treatment. METHODS:Medline,Cochrane library,PubMed,EMBase,VIP database,CJFD and Wanfang database were retrieved to collect the randomized controlled trials(RCT)of comparison treatment(test group)of acar-bose and placebo(control group)in IGT. After the information collection and quality evaluation,Rev Man 5.0 was conducted for Mata-analysis. RESULTS:26 RCT,involving 2 221 patients were include in total. Meta-analysis result showed,compared with place-bo,acarbose could reduce FPG[WMD=-0.76,95%CI(-0.99,-0.53),P<0.001],2 h PG[WMD=-1.58,95%CI(-1.82,-1.34), P<0.001],HbA1c[WMD=-0.46,95%CI(-0.82,-0.11),P=0.01],BMI[WMD=-1.10,95%CI(-1.77,-0.44),P=0.001], TC[WMD=-0.35,95%CI(-0.59,-0.12),P=0.003],TG[WMD=-0.30,95%CI(-0.44,-0.16),P<0.001] significantly;it had no significant difference on HDL-C[WMD=-0.05,95%CI(-0.11,0.01),P=0.11] and LDL-C[WMD=-0.13,95%CI(-0.31, 0.05),P=0.17]. CONCLUSIONS:Acarbose has better efficacy in the treatment of IGT. Due to the low quality of included studies, it remains to be further verified by RCT with large sample and high quality.